209 related articles for article (PubMed ID: 33737511)
1. HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.
Massey AJ; Schoepfer J; Brough PA; Brueggen J; Chène P; Drysdale MJ; Pfaar U; Radimerski T; Ruetz S; Schweitzer A; Wood M; Garcia-Echeverria C; Jensen MR
Mol Cancer Ther; 2010 Apr; 9(4):906-19. PubMed ID: 20371713
[TBL] [Abstract][Full Text] [Related]
3. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
Menezes DL; Taverna P; Jensen MR; Abrams T; Stuart D; Yu GK; Duhl D; Machajewski T; Sellers WR; Pryer NK; Gao Z
Mol Cancer Ther; 2012 Mar; 11(3):730-9. PubMed ID: 22246440
[TBL] [Abstract][Full Text] [Related]
4. Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma.
Meng J; Liu Y; Han J; Tan Q; Chen S; Qiao K; Zhou H; Sun T; Yang C
Mol Cancer; 2017 Mar; 16(1):72. PubMed ID: 28359326
[TBL] [Abstract][Full Text] [Related]
5. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
[TBL] [Abstract][Full Text] [Related]
6. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of Hsp90 in childhood acute lymphoblastic leukaemia.
Diamanti P; Cox CV; Moppett JP; Blair A
Br J Haematol; 2018 Jan; 180(1):147-149. PubMed ID: 27503106
[No Abstract] [Full Text] [Related]
8. Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800.
Stühmer T; Chatterjee M; Grella E; Seggewiss R; Langer C; Müller S; Schoepfer J; Garcia-Echeverria C; Quadt C; Jensen MR; Einsele H; Bargou RC
Br J Haematol; 2009 Nov; 147(3):319-27. PubMed ID: 19686236
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.
Tabata M; Tsubaki M; Takeda T; Tateishi K; Maekawa S; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
Clin Exp Med; 2020 Feb; 20(1):63-71. PubMed ID: 31650359
[TBL] [Abstract][Full Text] [Related]
10. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
11. Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice.
Milani M; Laranjeira AB; de Vasconcellos JF; Brandalise SR; Nowill AE; Yunes JA
PLoS One; 2015; 10(6):e0129298. PubMed ID: 26068922
[TBL] [Abstract][Full Text] [Related]
12. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Kucine N; Marubayashi S; Bhagwat N; Papalexi E; Koppikar P; Sanchez Martin M; Dong L; Tallman MS; Paietta E; Wang K; He J; Lipson D; Stephens P; Miller V; Rowe JM; Teruya-Feldstein J; Mullighan CG; Ferrando AA; Krivtsov A; Armstrong S; Leung L; Ochiana SO; Chiosis G; Levine RL; Kleppe M
Blood; 2015 Nov; 126(22):2479-83. PubMed ID: 26443624
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
16. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
17. HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.
Tavernier E; Flandrin-Gresta P; Solly F; Rigollet L; Cornillon J; Augeul-Meunier K; Stephan JL; Montmartin A; Viallet A; Guyotat D; Campos L
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1753-8. PubMed ID: 22706881
[TBL] [Abstract][Full Text] [Related]
18. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
Tong WG; Estrov Z; Wang Y; O'Brien S; Faderl S; Harris DM; Van Pham Q; Hazan-Halevy I; Liu Z; Koch P; Kantarjian H; Keating MJ; Ferrajoli A
Invest New Drugs; 2011 Dec; 29(6):1206-12. PubMed ID: 20533075
[TBL] [Abstract][Full Text] [Related]
19. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
Fu J; Koul D; Yao J; Wang S; Yuan Y; Colman H; Sulman EP; Lang FF; Yung WK
Cancer Res; 2013 May; 73(10):3062-74. PubMed ID: 23492364
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
Fujii Y; Amano M; Seriu T
Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
[No Abstract] [Full Text] [Related]
[Next] [New Search]